Teva announces update on Fremanezumab clinical development for episodic cluster headache
Teva announces it is discontinuing clinical development program for use of fremanezumab in cluster headaches. A pre-specified futility analysis of a Phase III study in episodic cluster headache revealed that the study’s primary endpoint is unlikely to be met. April 23, 2019